CN1883666A - Pharmaceutical composition for treating nephritis - Google Patents
Pharmaceutical composition for treating nephritis Download PDFInfo
- Publication number
- CN1883666A CN1883666A CN 200610020883 CN200610020883A CN1883666A CN 1883666 A CN1883666 A CN 1883666A CN 200610020883 CN200610020883 CN 200610020883 CN 200610020883 A CN200610020883 A CN 200610020883A CN 1883666 A CN1883666 A CN 1883666A
- Authority
- CN
- China
- Prior art keywords
- parts
- pharmaceutical composition
- cortex
- herba
- nephritis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention discloses a pharmaceutical composition for treating nephritis wherein the raw material herbs include (by weight ratio) Chinese ephedra 1-15 parts, calcium sulphate 5-30 parts, yellow corktree bark 5-30 part, honeysuckle flower 5-30 parts, capsule of weeping forsythia 10-30 parts, aristolochia stem 1-20 parts, seed of Job's tears 30-50 parts, alisol 1-20 parts, polyporus umbellatus 1-20 parts, areca catecha 1-20 parts and cordate houttuynia 30-50 parts.
Description
Technical field
The present invention relates to a kind of pharmaceutical composition for the treatment of nephritis.
Background technology
Nephritis is the apyogenous inflammatory lesion of both sides kidney.Phenomenons such as edema, hypertension, albuminuria appear in kidney because of renal corpuscle suffers damage, be modal a kind of in the kidney disease.In case suffer from nephritis, if control is improper,, can engender that renal function goes down, renal dysfunction etc. along with the development of the state of an illness, gently disability then influences patient's operate as normal and learning life; Heavy then lose one's life the serious harm human health.
The nephritis kind is a lot, as acute (glomerule) nephritis, chronic (glomerule) nephritis, pyelonephritis, latent nephritis, Henoch Schonlein purpura nephritis (henoch Schonlein purpura nephritis), lupus erythematosus nephritis (lupus nephritis) etc.Modal have acute glomerulonephritis, chronic glomerulonephritis, a pyelonephritis etc.
Acute glomerulonephritis is a kind of because the both sides kidney diffusivity glomerule infringement that allergy causes after infecting is main acute illness, the characteristics of primary disease are that onset is more anxious, and serial clinical manifestations such as hematuria, albuminuria, cylinderuria, edema, oliguria, hypertension appear in 1-3 week after infection.
Chronic glomerulonephritis is that (even many decades) of group leader's course of disease of causing of various primary glomerulopathies is the disease of clinical manifestation with albuminuria, hematuria, edema, hypertension; It is the one group of renal glomerular disease that causes by Different types of etiopathogenises.This disease is common, especially with male adults sickness rate height.Primary disease treatment difficulty, progressive mostly is chronic renal failure, prognosis is relatively poor.The chronic nephritis later stage can be developed into renal insufficiency so that renal failure---uremia, and anemia, heart failure etc. can appear in the patient.
To acute and chronic glomerulonephritis, still there is not special effect medicine therapeutic at present, substantially based on symptomatic treatment and control complication.Symptomatic treatment is as diuresis, thiazide diuretic commonly used; Blood pressure lowering, thiazide diuretic commonly used, vasodilator, available in case of necessity ganglionic block agents, or add and use calcium ion channel blocker; The treatment of hyperkalemia is based on restriction potassium increased diet and the row's of application potassium diuretic.The treatment of complication as: the control heart failure focuses on correcting water-sodium retention, recovers blood volume; Hypertensive encephalopathy, medicines such as intravenous drip sodium nitroprusside, the tiqueur can use stable intravenous injection etc.In addition, also can use antibiotic therapies such as penicillin or Macrolide, and adopt hormone etc. to carry out maintenance treatment the relatively obstinate symptoms such as albuminuria of chronic nephritis with the control infection focus.
Pyelonephritis is directly to attack the struvite disease disease that renal pelvis, excess of the kidney matter cause by apparent specificity antibacterial, is the commonly encountered diseases of urinary tract infection, good sending out in 20-40 year women's (ratio of men and women's morbidity is about 1: 10).Pathogenic bacterium are most to be gram negative bacilli, the most common with escherichia coli.Pyelonephritis has acute stage and two stages of chronic phase.Acute stage, mainly show as heating, frequent micturition, urgent micturition, dysurea and lumbar and back pain etc., and the urine routine examination can be found leukocyte (pus cell) and antibacterial.Chronic phase,, symptom was generally lighter, can be delayed by acute stage; Though or acute stage control, develop through outbreak repeatedly.
Antibacterials are also often selected in the treatment of pyelonephritis, as the mute azoles of sulfamethoxine or Synergic Sulphonamides Compound Tablets or cephalexin or ampicillin, cefobid etc., perhaps drug combination.General acute pyelonephritis all can be cured rapidly more than 90%; Chronic person cures then relatively difficulty, generally needs to adopt two or more medication combined uses.
But, for these treat the conventional means of nephritis at present, still there is the problem of all many-sides, as: symptomatic treatment and control complication can not be cured this disease from root, and refractory is treated thorough, so easily outbreak repeatedly of the state of an illness.Antibiotic therapy also usually can produce drug resistance; curative effect obviously descends behind the life-time service; the state of an illness is easily outbreak repeatedly also; also may produce some serious adverse effects such as anemia, thrombocytopenia, leukopenia etc. simultaneously, thereby also can cause the interior normal flora imbalance of human body to cause new disease etc.And if adopt hormonotherapy because hormone is stronger to the masking property of the state of an illness, side effect is obvious, and easily recurrence, generally also unsuitable life-time service.In addition, nephritis patient often needs long-term prescription, and equal price gangster not such as the medicine of these symptomatic treatments and antibiotics, hormone, often makes the patient in spirit with all can't bear the heavy load economically.
At present, the traditional Chinese medical science has obtained remarkable progress in the research aspect the treatment nephropathy, adopts suitable treatment by Chinese herbs nephritis, curative effect is obvious on the one hand, is difficult for recurrence, on the other hand, no pain, have no side effect, expense is low, thereby more and more is subjected to the favor of clinician and numerous nephritis patients; But the Chinese patent medicine that can be used for the treatment of nephritis at present also has only minority kinds such as BUZHONG YIQI WAN, and other has some kinds still to be in conceptual phase, also can not satisfy the needs of nephritis patient clinical treatment far away.
Summary of the invention
The purpose of this invention is to provide a kind of new pharmaceutical composition for the treatment of nephritis.Curative effects such as the acute and chronic nephritis of this medicine composite for curing, pyelonephritis are reliable; No obvious adverse reaction, safety is good; And with low cost, medical expense is low.
The technical solution adopted for the present invention to solve the technical problems is: a kind of pharmaceutical composition for the treatment of nephritis, and it comprises following raw materials in weight portion medicine:
Herba Ephedrae 1-15 part Gypsum Fibrosum 5-30 part Cortex Phellodendri 5-30 part Flos Lonicerae 5-30 part
Fructus Forsythiae 10-30 part Caulis Akebiae 1-20 part Semen Coicis 30-50 part Rhizoma Alismatis 1-20 part
Polyporus 1-20 part Pericarpium Arecae 1-20 part Herba Houttuyniae 30-50 part.
The weight portion proportion optimization of above-mentioned each crude drug is:
Herba Ephedrae 5-10 part Gypsum Fibrosum 10-20 part Cortex Phellodendri 10-20 part Flos Lonicerae 10-20 part
Fructus Forsythiae 15-25 part Caulis Akebiae 5-15 part Semen Coicis 35-45 part Rhizoma Alismatis 5-15 part
Polyporus 5-15 part Pericarpium Arecae 5-15 part Herba Houttuyniae 35-45 part.
The weight portion proportioning of above-mentioned each crude drug is more preferably:
15 parts of 14 parts of Flos Lonicerae of 14 portions of Cortex Phellodendris of 8 parts of Gypsum Fibrosum of Herba Ephedrae
12 parts of 40 portions of Rhizoma Alismatis of 10 parts of Semen Coiciss of 20 portions of Caulis Akebiaes of Fructus Forsythiae
40 parts of 10 parts of Herba Houttuyniae of 10 parts of Pericarpium Arecae of Polyporus.
Pharmaceutical composition of the present invention can also contain following raw materials in weight portion medicine except that containing the above-mentioned raw materials medicine: Cortex Sclerotii Poriae 35-45 part, CORTEX ZINGIBERIS RHIZOMAE 5-15 part, Rhizoma Atractylodis Macrocephalae 10-15 part, Herba Plantaginis core 10-15 part.Its preferred weight part proportioning is 40 parts of Cortex Sclerotii Poriae, 10 parts of CORTEX ZINGIBERIS RHIZOMAE, 12 parts of the Rhizoma Atractylodis Macrocephalaes, 12 parts of Herba Plantaginis core.
Pharmaceutical composition of the present invention can adopt process for preparing medicine commonly used, make any one possible on pharmaceutics pharmaceutical dosage form after each crude drug is extracted, and preferably makes the medicine of peroral dosage form, as tablet, capsule, syrup, oral liquid etc.And the needs according to preparation different dosage form medicine can add suitable pharmaceutic adjuvant.
Compared with prior art, the invention has the beneficial effects as follows: pharmaceutical composition of the present invention is made up of ten pleasant impression Chinese medicines of meticulous screening, each set of dispense is than suitable, the cause of disease and clinical symptoms at multiple nephritis, etiological treatment and symptomatic treatment are combined, have effects such as antiinflammatory, sterilization, diuresis, and can remove renal blood vessels spasm, blood circulation promoting, impel kidney to get well.And it is reliable to prove that through clinical research it treats curative effects such as acute and chronic nephritis, pyelonephritis; And do not have obvious adverse reaction, safety is good.In addition, the raw materials used medicine of pharmaceutical composition of the present invention is with low cost, and medical expense is lower.
The specific embodiment
The present invention is described in further detail below in conjunction with the specific embodiment.
Embodiment 1
The present embodiment pharmaceutical composition is made by following weight parts proportion raw material medicine:
15 parts of 14 parts of Flos Lonicerae of 14 portions of Cortex Phellodendris of 8 parts of Gypsum Fibrosum of Herba Ephedrae
12 parts of 40 portions of Rhizoma Alismatis of 10 parts of Semen Coiciss of 20 portions of Caulis Akebiaes of Fructus Forsythiae
40 parts of 10 parts of Herba Houttuyniae of 10 parts of Pericarpium Arecae of Polyporus.
Embodiment 2
The present embodiment pharmaceutical composition is made by following weight parts proportion raw material medicine:
30 parts of 20 parts of Flos Lonicerae of 10 portions of Cortex Phellodendris of 5 parts of Gypsum Fibrosum of Herba Ephedrae
5 parts of 35 portions of Rhizoma Alismatis of 20 parts of Semen Coiciss of 15 portions of Caulis Akebiaes of Fructus Forsythiae
35 parts of 5 parts of Herba Houttuyniae of 15 parts of Pericarpium Arecae of Polyporus.
Embodiment 3
The present embodiment pharmaceutical composition is made by following weight parts proportion raw material medicine:
10 parts of 5 parts of Flos Lonicerae of 20 portions of Cortex Phellodendris of 15 parts of Gypsum Fibrosum of Herba Ephedrae
20 parts of 45 portions of Rhizoma Alismatis of 1 part of Semen Coicis of 25 portions of Caulis Akebiaes of Fructus Forsythiae
45 parts of 1 part of Herba Houttuyniae of 1 part of Pericarpium Arecae of Polyporus.
Embodiment 4
The present embodiment pharmaceutical composition is made by following weight parts proportion raw material medicine:
5 parts of 10 parts of Flos Lonicerae of 30 portions of Cortex Phellodendris of 10 parts of Gypsum Fibrosum of Herba Ephedrae
1 part of 50 portions of Rhizoma Alismatis of 15 parts of Semen Coiciss of 10 portions of Caulis Akebiaes of Fructus Forsythiae
30 parts of 20 parts of Herba Houttuyniae of 20 parts of Pericarpium Arecae of Polyporus.
Embodiment 5
The present embodiment pharmaceutical composition is made by following weight parts proportion raw material medicine:
20 parts of 30 parts of Flos Lonicerae of 5 portions of Cortex Phellodendris of 1 part of Gypsum Fibrosum of Herba Ephedrae
15 parts of 30 portions of Rhizoma Alismatis of 5 parts of Semen Coiciss of 30 portions of Caulis Akebiaes of Fructus Forsythiae
50 parts of 15 parts of Herba Houttuyniae of 5 parts of Pericarpium Arecae of Polyporus.
Embodiment 6
The present embodiment pharmaceutical composition is made by following weight parts proportion raw material medicine:
15 parts of 14 parts of Flos Lonicerae of 14 portions of Cortex Phellodendris of 8 parts of Gypsum Fibrosum of Herba Ephedrae
12 parts of 40 portions of Rhizoma Alismatis of 10 parts of Semen Coiciss of 20 portions of Caulis Akebiaes of Fructus Forsythiae
12 parts of 10 parts of Rhizoma Atractylodis Macrocephalaes of 40 parts of CORTEX ZINGIBERIS RHIZOMAE of 10 parts of Cortex Sclerotii Poriae of Polyporus
40 parts of 10 parts of Herba Houttuyniae of 12 parts of Pericarpium Arecae of Herba Plantaginis core.
Embodiment 7
The present embodiment pharmaceutical composition is made by following weight parts proportion raw material medicine:
25 parts of 25 parts of Flos Lonicerae of 25 portions of Cortex Phellodendris of 12 parts of Gypsum Fibrosum of Herba Ephedrae
10 parts of 36 portions of Rhizoma Alismatis of 8 parts of Semen Coiciss of 18 portions of Caulis Akebiaes of Fructus Forsythiae
15 parts of 15 parts of Rhizoma Atractylodis Macrocephalaes of 35 parts of CORTEX ZINGIBERIS RHIZOMAE of 18 parts of Cortex Sclerotii Poriae of Polyporus
42 parts of 12 parts of Herba Houttuyniae of 10 parts of Pericarpium Arecae of Herba Plantaginis core.
Embodiment 8
The present embodiment pharmaceutical composition is made by following weight parts proportion raw material medicine:
18 parts of 18 parts of Flos Lonicerae of 15 portions of Cortex Phellodendris of 6 parts of Gypsum Fibrosum of Herba Ephedrae
8 parts of 32 portions of Rhizoma Alismatis of 12 parts of Semen Coiciss of 12 portions of Caulis Akebiaes of Fructus Forsythiae
10 parts of 5 parts of Rhizoma Atractylodis Macrocephalaes of 45 parts of CORTEX ZINGIBERIS RHIZOMAE of 12 parts of Cortex Sclerotii Poriae of Polyporus
36 parts of 6 parts of Herba Houttuyniae of 15 parts of Pericarpium Arecae of Herba Plantaginis core.
In the various embodiments described above, all can be by extract drugs, the preparation method of various routines, after each crude drug extraction, concentrating, add suitable pharmaceutic adjuvant, according to the formulation method of routine, make the medicine of various different dosage forms, different size again, as tablet, capsule, syrup, oral liquid etc.
The model case brief introduction:
Case one: Liu * *, bearing township, Yilong, Sichuan field town resident, the woman, 40 years old, it was many January to suffer from acute nephritis, oliguria, whole body severe edema; Urine examination is erythrocyte as a result ++, pus cell +++.Take medicine of the present invention (being embodiment 1 described medicine, down together) after 16 days, transference cure, urine examination is normal.
Case two: old * *, Yilong, Sichuan three flood dragon village people, the man, 45 years old, be diagnosed as chronic pyelonephritis through the county hospital chemical examination, puffiness of face, oliguria, lumbago are more than 2 years.Taking medicine of the present invention fully recovered after 22 days.
Case three: Wu * *, public village people is opened in the Yilong, Sichuan, the woman, and 22 years old, puffiness of face, lumbago, oliguria, urine examination is erythrocyte as a result ++, albumen ++, the hospitalization first quarter moon is many in local hospital, and the symptom shape does not subtract.Taking medicine of the present invention fully recovered after 30 days.
Case four: Cai * *, Yilong, Sichuan new people village people, the woman, 45 years old, puffiness of face, oliguria, lumbago more than 7 years, were diagnosed as chronic glomerulonephritis through local county hospital.Taking medicine of the present invention fully recovered after 36 days.
Case five: old * *, Xinhua township, Yilong, Sichuan people from Changle Village, oliguria, the whole body Mild edema, urine examination is erythrocyte+ten as a result, albumen ++, pus cell ++, in the county, district hospital's hospitalization more than four months, the state of an illness is even more serious, is critically ill.Take medicine of the present invention after 35 days, transference cure, urine examination is normal, never recurrence.
By patients' such as above-mentioned acute and chronic glomerulonephritis, pyelonephritis treatment, use the curative effect highly significant of medicine of the present invention, do not see obvious adverse reaction, safe and reliable.
Claims (6)
1. pharmaceutical composition for the treatment of nephritis, it comprises following raw materials in weight portion medicine:
Herba Ephedrae 1-15 part Gypsum Fibrosum 5-30 part Cortex Phellodendri 5-30 part Flos Lonicerae 5-30 part
Fructus Forsythiae 10-30 part Caulis Akebiae 1-20 part Semen Coicis 30-50 part Rhizoma Alismatis 1-20 part
Polyporus 1-20 part Pericarpium Arecae 1-20 part Herba Houttuyniae 30-50 part.
2. the pharmaceutical composition of treatment nephritis according to claim 1 is characterized in that: the weight portion proportioning of described each crude drug is:
Herba Ephedrae 5-10 part Gypsum Fibrosum 10-20 part Cortex Phellodendri 10-20 part Flos Lonicerae 10-20 part
Fructus Forsythiae 15-25 part Caulis Akebiae 5-15 part Semen Coicis 35-45 part Rhizoma Alismatis 5-15 part
Polyporus 5-15 part Pericarpium Arecae 5-15 part Herba Houttuyniae 35-45 part.
3. the pharmaceutical composition of treatment nephritis according to claim 2 is characterized in that: the weight portion proportioning of described each crude drug is:
15 parts of 14 parts of Flos Lonicerae of 14 portions of Cortex Phellodendris of 8 parts of Gypsum Fibrosum of Herba Ephedrae
12 parts of 40 portions of Rhizoma Alismatis of 10 parts of Semen Coiciss of 20 portions of Caulis Akebiaes of Fructus Forsythiae
40 parts of 10 parts of Herba Houttuyniae of 10 parts of Pericarpium Arecae of Polyporus.
4. the pharmaceutical composition of treatment nephritis according to claim 1 is characterized in that: also contain following raw materials in weight portion medicine in the described pharmaceutical composition: Cortex Sclerotii Poriae 35-45 part, CORTEX ZINGIBERIS RHIZOMAE 5-15 part, Rhizoma Atractylodis Macrocephalae 10-15 part, Herba Plantaginis core 10-15 part.
5. the pharmaceutical composition of treatment nephritis according to claim 4 is characterized in that: the weight portion proportioning of described crude drug Cortex Sclerotii Poriae, CORTEX ZINGIBERIS RHIZOMAE, the Rhizoma Atractylodis Macrocephalae, Herba Plantaginis core is: 40 parts of Cortex Sclerotii Poriae, 10 parts of CORTEX ZINGIBERIS RHIZOMAE, 12 parts of the Rhizoma Atractylodis Macrocephalaes, 12 parts of Herba Plantaginis core.
6. according to the pharmaceutical composition of each described treatment nephritis among the claim 1-5, it is characterized in that: described pharmaceutical composition is the medicine of peroral dosage form.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200610020883 CN1883666A (en) | 2006-05-24 | 2006-05-24 | Pharmaceutical composition for treating nephritis |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200610020883 CN1883666A (en) | 2006-05-24 | 2006-05-24 | Pharmaceutical composition for treating nephritis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN1883666A true CN1883666A (en) | 2006-12-27 |
Family
ID=37582050
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 200610020883 Pending CN1883666A (en) | 2006-05-24 | 2006-05-24 | Pharmaceutical composition for treating nephritis |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1883666A (en) |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102836403A (en) * | 2012-08-09 | 2012-12-26 | 王迪峰 | Chinese medicine for treating chronic nephritis by using root of low greenbrier |
| CN103432467A (en) * | 2013-07-26 | 2013-12-11 | 张启锐 | Traditional Chinese medicine used for treating uremia and preparation method thereof |
| CN104706991A (en) * | 2013-12-11 | 2015-06-17 | 天津嘉创生物科技有限公司 | Traditional Chinese medicine oral liquid for treating bovine nephritis and preparation method thereof |
| CN104758705A (en) * | 2015-04-24 | 2015-07-08 | 王立昌 | Traditional Chinese medicine composition for treating chronic glomerulo nephritis and preparation method thereof |
| CN106236971A (en) * | 2016-08-29 | 2016-12-21 | 长沙佰顺生物科技有限公司 | A kind of Chinese medicine composition treating chronic nephritis |
| CN108420920A (en) * | 2018-06-14 | 2018-08-21 | 陈影 | A kind of Chinese medicine composition and preparation method thereof for controlling edema type ephritis |
-
2006
- 2006-05-24 CN CN 200610020883 patent/CN1883666A/en active Pending
Cited By (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102836403A (en) * | 2012-08-09 | 2012-12-26 | 王迪峰 | Chinese medicine for treating chronic nephritis by using root of low greenbrier |
| CN102836403B (en) * | 2012-08-09 | 2014-07-02 | 王迪峰 | Chinese medicine for treating chronic nephritis by using root of low greenbrier |
| CN103432467A (en) * | 2013-07-26 | 2013-12-11 | 张启锐 | Traditional Chinese medicine used for treating uremia and preparation method thereof |
| CN103432467B (en) * | 2013-07-26 | 2015-03-18 | 张启锐 | Traditional Chinese medicine used for treating uremia and preparation method thereof |
| CN104706991A (en) * | 2013-12-11 | 2015-06-17 | 天津嘉创生物科技有限公司 | Traditional Chinese medicine oral liquid for treating bovine nephritis and preparation method thereof |
| CN104758705A (en) * | 2015-04-24 | 2015-07-08 | 王立昌 | Traditional Chinese medicine composition for treating chronic glomerulo nephritis and preparation method thereof |
| CN106236971A (en) * | 2016-08-29 | 2016-12-21 | 长沙佰顺生物科技有限公司 | A kind of Chinese medicine composition treating chronic nephritis |
| CN108420920A (en) * | 2018-06-14 | 2018-08-21 | 陈影 | A kind of Chinese medicine composition and preparation method thereof for controlling edema type ephritis |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN100342889C (en) | Chinese medicine for treating gout | |
| CN1883666A (en) | Pharmaceutical composition for treating nephritis | |
| CN100344306C (en) | Medicine composition for treating urinary system stone and inflammation | |
| CN102274334A (en) | Medicine for treating rhinitis and preparation method thereof | |
| CN1157219C (en) | Medicine for treating cancer | |
| CN1054541C (en) | Traditional Chinese medicine for treating mastosis | |
| CN1155380C (en) | Application of sophocarpidine oxide in preparing medicine to treat ulcerative colitis | |
| CN102274428B (en) | Pharmaceutical composition with effect on treating irritable bowel syndrome and preparation method and application thereof | |
| CN1186067C (en) | Medicine for curing acute injury of muscle and tendon and its preparation method | |
| CN1319587C (en) | Medicine powder for liver and spleen diseases | |
| CN1160102C (en) | Chinese medicine for curing female chronic inflammation | |
| CN1251751C (en) | Chinese traditional medicine for treating chronic liver disease and anti hepatic fibrosis | |
| CN1244369C (en) | Medicine for treating xerosis syndrome and its preparing process | |
| CN1186028C (en) | Antagesic Chinese medicine and its preparing process and usage | |
| CN1726983A (en) | Plaster for treating prolapes of lumbar inttervertebral disc | |
| CN1891281A (en) | Chinese medicine preparation for treating wind-cold disease, and its preparing method | |
| CN1562222A (en) | Medicination for curing kidney disease and preparation method | |
| CN1172694C (en) | Medicine for treating bone tuberculosis | |
| CN1323656C (en) | Medicine for treating rheumatic arthritis and preparation technology of its spray agent | |
| CN1212132C (en) | Chinese medicine for treating rheumatic diseases and its prepn | |
| CN1199639C (en) | Medicine for curing subacute thyroiditis | |
| CN1895631A (en) | Chinese medicine for treating urinaemia | |
| CN1239179C (en) | Chinese medicine for treating diabetes and preparation method therefor | |
| CN1899544A (en) | Medicine for treating pile | |
| CN101066393A (en) | Recipe of medicine for treating uremia, acute and chronic nephritis and their complication |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| AD01 | Patent right deemed abandoned | ||
| C20 | Patent right or utility model deemed to be abandoned or is abandoned |